Human tissue factor pathway inhibitor-2 suppresses the wound-healing activities of human Tenon’s capsule fibroblasts in vitro by Jing, Yuan & Jian-Xiong, Yu
Human tissue factor pathway inhibitor-2 suppresses the wound-
healing activities of human Tenon’s capsule fibroblasts in vitro
Yuan Jing,1 Yu Jian-Xiong2
1Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, China; 2Department of Gastrointestinal Surgery,
Renmin Hospital of Wuhan University, Wuhan, China
Purpose:  Human  tissue  Factor  Pathway  Inhibitor-2  (TFPI-2)  is  a  potent  inhibitor  of  plasmin,  which  activates
metalloproteinases involved in extracellular matrix degradation. Its secretion in the extracellular matrix makes TFPI-2 a
potential inhibitor of tumor cell invasion. However, no studies have yet evaluated the wound-healing activities of human
Tenon’s capsule fibroblasts (hTCFs). The aim of the study is to elucidate the effect of TFPI-2 overexpression on hTCF
proliferation and migration, to determine whether TFPI-2 may act as an antiscarring agent in vivo after glaucoma filtration
surgery.
Methods: Plasmid vector pBos-Cite-neo/TFPI-2 was transfected into hTCFs with Lipofectamine 2000. After selection
by G418, transfected, non-transfected, and mock-transfected cells were screened for TFPI-2 mRNA and protein by reverse
transcription-PCR and western blot analysis respectively. Cell proliferation and viability were determined by 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry. Cell migration was studied on
restrained collagen gels and with a scratch-wound assay.
Results: TFPI-2 expression of mRNA and protein was confirmed in transfected cells. The transfected, non-transfected,
and mock-transfected cells showed no significant difference in cell proliferation and apoptosis, with TFPI-2 found not to
be cytotoxic in hTCFs. Overexpression of TFPI-2 significantly suppressed cell migration three- to four-fold on collagen
gel for 2 weeks and in the scratch-wound assay for 2 d (39.27±2.40% versus 16.43±1.10% at 1 d, and 79.0±3.04% versus
30.13±2.1% at 2 d).
Conclusions: TFPI-2 expression may strongly inhibit the migration ability of hTCFs in vitro, making it a promising
candidate for novel therapies to minimize scar development after glaucoma drainage surgery.
Trabeculectomy  is  the  most  frequently  used  surgical
method  to  reduce  intraocular  pressure  in  patients  with
glaucoma  unresponsive  to  medical  therapy.  However,
excessive  scarring  of  the  filtering  bleb  after  glaucoma
filtration  surgery  can  lead  to  an  increase  in  intraocular
pressure, and is the most important cause of treatment failure.
A  variety  of  antimetabolites,  such  as  5-fluorouracil  and
mitomycin C, has been shown to be clinically effective at
preventing bleb failure after filtration surgery [1,2]. Their
antifibrotic effect has been shown to derive mostly from the
inhibition  of  human  Tenon’s  capsule  fibroblasts  (hTCFs)
proliferation,  as  well  as  from  apoptotic  cell  death  [3].
However, these agents are associated with significant adverse
side effects and postoperative complications, such as ocular
hypotony,  following  choroidal  detachment  and  hypotonic
maculopathy,  progressive  thinning  of  the  filtering  bleb
following  bleb  infection,  and  endophthalmitis  [4,5].  Most
studies on the filtering bleb healing process and its modulation
have concentrated on fibroblast proliferation. However, in
some high-risk patients, even after antiproliferative treatment,
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surgery still fails, in part due to residual activity of the growth-
arrested cells and their interaction with surrounding untreated
fibroblasts.  Therefore,  alternative  targets  to  prevent  scar
formation after trabeculectomy are needed.
The  wound-healing  processes  include  proliferation,
migration,  synthesis  of  extracellular  matrix  (ECM)
components, and collagen contraction by hTCFs (the key cells
involved  in  the  subconjunctival  wound-healing  response).
After injury, quiescent fibroblasts in the surrounding matrix
are activated; they proliferate, and migrate into the wound site
to  deposit  and  remodel  a  new  matrix,  resulting  in  tissue
fibrosis and scar formation. This process involves a family of
enzymes capable of cleaving components of the ECM, such
as matrix metalloproteinases (MMPs). Human tissue factor
pathway inhibitor-2 (TFPI-2), an inhibitor of MMPs, may
inhibit scarring after glaucoma filtration surgery. TFPI-2 is a
member of the same Kunitz-type serine protease inhibitor
family as tissue factor pathway inhibitor-1 (TFP-1). TFPI-2
contains three Kunitz domains arranged in tandem with a high
degree of conservation. The basic carboxy terminus of TFPI-2
mediates ionic interactions that associate this protein with
glycosaminoglycans  in  ECMs  [6,7].  Studies  have
demonstrated that TFPI-2 is a strong serine protease inhibitor
with broad inhibitory spectra, whose expression can decrease
the invasion capacity of various tumor cells [8-12]. Its effect
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2306on  the  wound-healing  activities  of  hTCFs  is  unknown.
Therefore, the aim of the present study was to elucidate the
effect  of  TFPI-2  on  hTCF  proliferation  and  migration  to
determine its suitability as an antiscarring agent for in vivo
use after glaucoma filtration surgery.
METHODS
Cell  culture:  Cultures  of  human  Tenon's  capsule  were
established from patients undergoing routine cataract surgery.
The tenets of the Declaration of Helsinki were followed in the
collection  of  human  material,  and  patients’  consent  was
obtained.  Excised  specimens  were  dissected  into  1-2  mm
cubes and maintained in Dulbecco's modified Eagle's medium
(Gibco BRL, Gaithersburg, MD), supplemented with 20 mM
HEPES, 10% fetal bovine serum (FCS), penicillin G (100 IU/
ml), streptomycin (100 μg/ml), and amphotericin B (0.25 mg/
ml), then cultured in an incubator at 37 °C in 5% carbon
dioxide and 95% humidified air. The hTCFs migrating from
these tissues were harvested and subcultured using 0.05%
trypsin and 0.02% EDTA (Gibco BRL, Gaithersburg, MD)
after approximately 2 weeks. Cells cultured for 4-5 passes
were used in this study. All experiments were repeated more
than twice.
Preparation and transformations of the human tissue factor
pathway  inhibitor-2  expression  vector:  The  TFPI-2
expression  vector  (pBos-Cite-neo/TFPI-2)  was  kindly
donated  by  Dr.  Zhong  Ren  (Department  of  Hematology,
Union Hospital, Wuhan, China). The plasmids were extracted
by  being  dissolved  in  alkali,  and  then  purified  using  a
precipitate of lithium chloride (LiCl) and polyethylene glycol
(PEG). Nucleic acid purity was estimated by light absorbance
of the 260 nm and 280 nm wavelengths. If the ratio of A260/
A280 was between 1.8 and 2.0, the DNA had high purity.
Then, plasmids were adjusted to 1.0 g/l and preserved at 4 ºC.
The TFPI-2 expression vector or the empty pBos-Cite-neo
vector  was  transfected  into  hTCFs  with  Lipofectamine
reagent (Gibco BRL, Gaithersburg, MD) according to the
manufacturer’s protocol. Transfected cells were selected and
cultured in medium containing 500 mg/ml of G418 (Gibco
BRL, Gaithersburg, MD) for 2-3 weeks. The colonized cells
were isolated, amplified, and used in subsequent experiments.
Reverse transcription-PCR and western blot analysis: Total
RNA was isolated with TRIzol Reagent (Invitrogen, Carlsbad,
CA). Reverse-transcription PCR (RT-PCR) was carried out
using the one-step RT-PCR system (Promega, Madison, WI).
The TFPI-2 primers were 5'-GTC GAT TCT GCT GCT TTT
CC-3' sense primer, corresponding to nucleotides 64-84 of the
published sequence [13] and 5'-ATG GAA TTT TCT TTG
GTG CG-3' antisense primer (nucleotide 484-504). Thirty-
five cycles were performed, at 94 ºC for 1 min, then at 60 ºC
for 1 min, then at 72 ºC for 1 min. β-Actin was amplified as
an internal control with primer 5'-GAA ACT ACC TTC AAC
TCC ATC-3' and antisense primer 5'-CGA GGC CAG GAT
GGA GCC GCC-3', with predicted products of 440 bp and
219 bp, respectively. Each reaction (5 μl) was separated on
1.5%  agarose  gel,  and  visualized  by  ethidium  bromide
staining and photography. Western blotting was carried out as
described  previously  [10].  Proteins  were  visualized  with
HRP-conjugated  anti-rabbit  immunoglobulin  G  (1:5000;
Figure 1. Identification and expression of tissue factor pathway inhibitor after gene transfection. A: Restriciton enzyme analysis of TFPI-2
plasmids digested with XbaI and KpnI. Line 1 is the 2-Log Marker. Line 2 is the pBos-Cite-neo/TFPI-2. Line 3 is the pBos-Cite-neo/TFPI-2
digested with XbaI and KpnI. Line 4 is the λDNA/EcoRI+HindIII Markers. B: Semi-quantification of TFPI-2 mRNA expression in hTCFs
after transfection with an empty vector or TFPI-2 expression vector was assessed by RT-PCR. RT-PCR for β-actin mRNA was performed as
a control. Relative OD Value (OD TFPI-2/OD β-actin) was used to evaluate the expression level of TFPI-2. Data are presented as mean value
±SD, the double asterisk indicates a p<0.001, Student’s t-test. C: Western blot analysis for the expression of TFPI-2 in hTCFs after transfection
with an empty vector or TFPI-2 expression vector. Each protein fraction was subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis on 15% acrylamide gels, transferred onto nitrocellulose membranes, and probed with a rabbit anti-human TFPI-2 antibody.
Molecular sizes of the detected bands are shown to be 33, 31, and 27 kDa.
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2307Santa Cruz Biotechnology, Inc., Santa Cruz, CA), followed
by western blotting (Pierce Biotechnology, Rockford, IL) and
photography.
Cell proliferation and analysis of apoptosis assay: 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide
(MTT)  cell  viability  assay  (CellTiter  96  Aqueous  One
Solution Cell Proliferation Assay; Promega, Madison, WI)
was  used  to  evaluate  cell  proliferation  following  the
manufacturer's instructions. Briefly, TFPI-2-transfected cells
(F-TFPI-2),  mock-transfected  cells  (F-V),  and  non-
transfected cells (F-P; all at 1×104 cells/ml) were seeded into
96-well plates and cultivated for 14 d. After days 2, 4, 6, 8,
10, 12, and 14, a 20 μl MTT stock solution (5 mg/ml) was
added to each well, and the cells were incubated at 37 °C for
3 h. The solution was discarded by gently inverting the plates,
and the wells were filled with 200 μl of lysis solution (0.6%
acetic  acid  and  10%  sodium  dodecyl  sulfate  in  dimethyl
sulfoxide). After the plates were shaken vigorously for 20 min,
absorbances in each well were read with a spectrophotometric
plate reader at 570 nm.
To  quantitate  apoptosis,  cells  from  F-P,  F-V,  and  F-
TFPI-2 were harvested, washed with cold PBS twice and
centrifuged 3X at 12,000 rpm for 5 min each at 4 ºC, The
staining of apoptotic cells was performed as follows: cells
were  resuspended  in  1X  binding  buffer,  with  cell
concentration adjusted to 1×106/ml. A cell suspension if 100
Figure  2.  MTT  cell  viability  assay  of  F-P,  F-V,  and  F-TFPI-2.
Extinctions of hTCFs were not significantly different among the
three groups, showing that either mock transfected cells or TFPI-2
transfected  cells  did  not  significantly  influence  metabolic  cell
proliferation activity.
μl was added to a tube, followed by 5 μl FITC-Annexin V
(Jingmei Biotech, Shenzhen, China) and 10 μl PI. The mixture
was incubated for 15 min in the dark at room temperature, and
400  μl  1×  binding  buffer  was  added.  Flow  cytometric
measurements were performed in a FACS Vantage sorter
(Becton  Dickinson,  Heidelberg,  Germany)  and  analyzed
using  CelQuest  software  (Becton  Dickinson,  Heidelberg,
Germany). The percentage of apoptotic cells was measured
and the data shown as the mean±SD of the results of three
independent experiments from each group.
Cell migration from spheroids: To evaluate hTCFs with or
without TFPI-2 transfection migration, collagen gels were
prepared by mixing a cold type I collagen solution with 10×
DMEM, 0.2 M HEPES, and 0.2 N NaOH on ice at a ratio of
8:1:1 (vol/vol/vol). Of this solution, 25 μl were cast on a sterile
slide placed in a 100 mm Petri dish. The gels were kept moist
by the addition of 1.0 ml of culture medium without serum,
and allowed to polymerize at 37 °C. Cells of F-P and F-TFPI-2
were harvested by trypsinization, resuspended in a culture
medium without serum at a density of 1×106 cells/ml, seeded
onto the polymerized gels, and allowed to form cell aggregates
for 2-3 h at 37 °C. The gels were then covered with culture
medium containing 10% FCS. The aggregate was incubated,
and the cells were allowed to migrate onto the collagen gel for
14 d. Immediately after cell attachment (T0) and at the time
points specified above for the 14 d incubation, images of cell
migration from the initial aggregates to the monolayers were
obtained  using  an  inverted  microscope  (Olympus  1×71,
Olympus Corporation, Tokyo, Japan) attached to a camera
(Olympus  DP12).  At  day  14,  the  cells  were  fixed  with
methanol for 10 min and processed for immunofluorescence
staining with Hoechst33342 (Hoechst Celanese, Frankfurt,
Germany).
Scratch-wound assay: F-TFPI-2 cells treated with or without
anti-TFPI-2 antibodies (Santa Cruz Biotechnology Inc., Santa
Cruz, CA) were harvested by trypsinization and seeded in 24-
well plates at a concentration of 5,000 cells/well, and then
grown until reaching confluence. F-P cells were seeded into
cultured  plates  as  a  control.  A  linear  wound  was  gently
introduced in the center of the cell monolayers using sterile
1.0 mm wide silicon strips, followed by extensive washing
with the growth medium to remove the cellular debris. Then,
the cells were incubated and wound closure monitored for 48
h. Cell images of marked regions along the wound area were
obtained  using  an  inverted  microscope  (Olympus  1×71)
attached  to  a  camera  (Olympus  DP12)  immediately  after
creating the wound and at 48 h.
Statistical analysis: Values are reported as mean±SD or as
median and range. Each experiment was repeated at least three
times.  Statistical  significance  of  the  differences  between
experimental  groups  was  determined  by  Student’s  t  test.
Differences were considered significant when p<0.05. All
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(SPSS, Inc., Chicago, IL).
RESULTS
Identification  and  expression  of  tissue  factor  pathway
inhibitor-2  after  gene  transfection:  After  pBos-Cite-neo/
TFPI-2 was digested by XbaI and KpnI, two fragments of 5.05
kb and 440 bp were seen in 1% agarose gel electrophoresis,
indicating 440 base pairs between the polyclonal sites XbaI
and KpnI (Figure 1A), confirming that the plasmid of pBos-
Cite-neo/ TFPI-2 contained the human TFPI-2 gene. The ratio
of OD260/OD280 was 1.80, indicating plasmid purity.
After 48 h, hTCFs were derived from areas around the
tissue.  On  days  4-5,  cells  grown  around  the  tissue  were
fusiform. At 2 weeks, cells were reticular. Subcultured cells
were  uniformly  fusiform.  Following  transfection  with
Lipofectamine 2000, cells were selected by G418, and stable
transfectants showed the same shape as non-transfected cells.
Both  the  mRNA  and  protein  expression  of  TFPI-2  were
confirmed after gene transfection by RT-PCR and western
blot, respectively. TFPI-2 mRNA was expressed strongly in
F-TFPI-2, but only slightly in F-V and F-P, suggesting that
hTCFs  strongly  expressed  TFPI-2  mRNA  after  being
transfected with TFPI-2 (Figure 1B). Consistent with RT-PCR
results, three apparent bands with molecular masses of 33, 31,
and 27 kDa were detected in the ECM of F-TFPI-2, but were
only weakly detected in the ECMs of F-V and F-P cells,
indicating  strong,  stable  TFPI-2  protein  expression  in  the
ECM of F-TFPI-2, but only slight expression in the ECMs of
F-V and F-P (Figure 1C).
Effect of tissue factor pathway inhibitor-2 on cell proliferation
and apoptosis: MTT cell viability assay allows evaluation of
cell metabolic activity such as cell number, cell metabolism,
and  mitochondrial  activation.  As  seen  in  Figure  2,  the
absorbance of the three groups did not differ significantly,
indicating that neither the vector construct itself nor TFPI-2
gene transfection significantly influenced cell proliferation.
By flow cytometry, we evaluated cell apoptosis. With
FITC-Annexin V/PI double staining, normal live cells were
represented as FITC-negative and PI-positive, early apoptotic
cells as FITC-positive and PI-negative, and necrotic cells as
FITC-positive and PI-positive. The percentage of apoptotic
cell populations in F-P, F-V, and F-TFPI-2 were, respectively,
4.09±0.09%,  4.14±0.06%,  and  4.22±0.07%  (again
respectively, p=0.129, F-P versus F-TFPI-2; p=0.196, F-V
versus  F-TFPI-2;  and  p=0.509,  F-P  versus  F-V).  This
indicated  no  significant  effect  on  cell  apoptosis  of  either
mock-transfected  cells  or  TFPI-2-transfected  cells.
Representative experiments are shown in Figure 3.
Human  tissue  factor  pathway  inhibitor-2  inhibits  human
Tenon’s capsule fibroblasts migration in vitro: To determine
whether  TFPI-2-mediated  cells  influence  migration,  we
observed the migration of sphere cells on restrained collagen
gels. As seen in Figure 4A,B, F-P, cells arranged in initial
spheroids spread out on the gel radially at 1 d, migrating to
6-8 times the initial size at 14 d. The confocal micrographs
showing blue nuclei staining with Hoechst33342 were equally
densely arranged, both at the inoculation zone (in the center)
and along the tracks leading to the farthest points reached by
the cells (at the periphery) at 14 d (Figure 4F,G). By contrast,
F-TFPI-2 cell migration was much lower. These cells had a
less  polarized  morphology,  had  no  significant  protruding
edge, appeared to be restricted to the inside of the gels (Figure
4C,D), and had reached only twice their initial size at 14 d.
Immunostaining of nuclei showed a more clonal arrangement
than F-P at the center and few cells at the periphery at 14 d.
The area occupied by cells was evaluated to quantify the
difference in cell migration between F-P and F-TFPI-2 at 14
d (Figure 4D).
In the scratch-wound assay, F-P cells and F-TFPI-2 cells
treated with anti-TFPI-2 Ab migrated into the wound area and
organized  a  dense  cellular  network,  resulting  in  nearly
complete  wound  recovery  after  2  d  (Figure  5A-C,G-I).
However, migration of F-TFPI-2 cells into the wound area
Figure 3. Contour diagram of FITC-Annexin V/PI flow cytometry of hTCFs for F-P, F-V, and F-TFPI-2. The lower right quadrant (region 4)
represents the apoptotic cells. The percentages of the apoptotic cells population were 4.0%, 4.2%, and 4.3%, respectively. One representative
experiment out of three was shown.
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Wound coverage, expressed as the percentage of the initial
area covered, represented the index of wound healing. Three
experiments for F-P, F-TFPI-2 treated with anti-TFPI-2 Ab,
and  F-TFPI-2  showed  wound  coverage,  respectively,  of
39.27±2.40%, 38.23±4.15%, and 16.43±1.10% on day 1, and
of  79.00±3.04%,  77.63±3.75%,  and  30.13±2.11%  at  48  h
(Figure 5J).
DISCUSSION
Most approaches to modifying the wound-healing response
after filtering surgery by gene transfer have concentrated on
hTCF proliferation. Recent studies show that hTCFs in the
focal area remain capable of migration and may contribute to
wound  scarring  even  after  antiproliferative  treatment  [2],
resulting in the failure of glaucoma filtration surgery. During
the scarring response, migration of active hTCFs involves
enhanced  proteolysis  and  the  means  to  prevent  excessive
ECM degradation, which would ultimately serve to inhibit
migration. TFPI-2, a 32 kDa serine proteinase inhibitor, is
known to play a regulatory role in several processes relevant
to the pathogenesis of tumor invasion [6-12]. In vitro, TFPI-2
inhibits  extracellular  proteolytic  activity  and  TF-mediated
coagulation.  It  may  also  influence  cell  migration  and
proliferation. However, we found no reports of the effect of
TFPI-2 on wound-healing in hTCFs. Hence, the present data
establishes the endogenous overexpression of TFPI-2, and for
the first time, shows by gene transfer that TFPI-2 inhibits the
temporal and spatial migration of hTCFs.
This study is the first to investigate the expression of
TFPI-2 after successful transfection of pBos-Cite-neo/TFPI-2
into cultured hTCFs. The results show that TFPI-2 mRNA and
protein were only slightly expressed in F-V and F-P, but
obviously expressed in F-TFPI-2 according to RT-PCR and
western  blot  analyses.  This  suggested  that  hTCFs  can
synthesize and secrete only an extraordinary small quantity of
TFPI-2,
, at levels insufficient to protect the integrity of ECMs
and block hTCFs in wound scarring. However, it may have
been  significantly  upregulated  by  gene  transfection.
Meanwhile, we observed cellular shape and proliferation after
Figure  4.  Effect  of  TFPI-2  on  the
migration of hTCFs on collagen gel. A-
D: Cells from F-P and F-TFPI-2 were
cultured on a restrained collagen gels in
the initial spheroids. They were allowed
to  migrate  for  1  day,  and  then  were
viewed under a microscope. E: An equal
amount of F-P and F-TFPI-2 cells were
inoculated on the collagen gels and the
changes in the areas occupied by cells
were monitored for 14 d. The multiple
of the initial area by the migration of
cells from the center of the spheroids to
the monolayers was measured using a
microscope calibrated with a stage and
ocular micrometer. The data shown are
the  mean  value±SD  of  the  results  of
three  independent  experiments  from
each  group.  The  double  asterisk
indicates a p value of <0.001, for the
Student’s  t-test.  F-I:  Representative
images of at the center and periphery of
the collagen gels are of the migration of
F-P and F-TFPI-2 after 14 d.
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cells,  indicating  that  increased  levels  of  TFPI-2  probably
resulted from increased expression of TFPI-2 per hTCF, rather
than from the presence of more cells. Our result was different
from that of Shinoda [14], who reported TFPI-2 could be
expressed in endothelial cells and act as a mitogen for vascular
smooth  muscle  cells,  indicating  that  the  cell  growth-
stimulation  of  TFPI-2  may  be  cell  type-dependent.  In
addition, we found no effect of TFPI-2 on hTCF apoptosis,
unlike  Tasiou  [15],  who  found  a  pro-apoptotic  effect  of
TFPI-2 in malignant human SNB19 gliomas after transfection
with sense TFPI-2 DNA. Kempaiah et al. [10] also found a
pro-apoptosis function of TFPI-2, after recombinant TFPI-2
protein was offered to HT-1080 cells by activated caspase-
mediated  signaling  pathways.  Because  no  such  role  was
observed in the present study, we assume the reason to be low
expression in normal cells, such as hTCFs, of the receptor to
tumor  necrosis  factor-related  apoptosis-inducing  ligand
(TRAIL).  As  measured  by  normal  cell  proliferation  and
viability, TFPI-2 was found not to be cytotoxic for hTCFs.
We evaluated the migration of hTCFs on collagen gel and
into a wound area created in a cell monolayer. The free-
floating  fibroblast-populated  collagen  model  in  vitro  is
thought to represent the matrix contraction exerted by the
tractional forces generated by cells in vivo as they migrate
through the matrix. The in vitro wound-healing model of
scraping cells and monitoring for migration to the edge of the
wound may be considered a prescreening model, to be used
to select for substances to treat wound healing in vivo. The
result showed that the administration of TFPI-2 significantly
suppresses  hTCF  migration  onto  the  restrained  collagen
matrix, as well as into a wound area, as shown by the absence
of  a  distinct  leading  or  trailing  edge.  Excluding  the
contribution  of  cell  proliferation  from  the  outcomes,  we
considered  the  moderately  increased  levels  of  TFPI-2
signaling to have indeed slowed the wound-healing process,
by reducing the number of hTCFs arriving on the collagen gel
or at the wound site. The upregulation of TFPI-2 as a potent
serine proteinase inhibitor may serve to limit proteolysis. This
involves the plasmin, trypsin, and matrix metalloproteinases
(MMPs) that are upregulated during wound healing, thereby
preventing  the  destruction  of  the  ECMs  required  for
migration. This is a surprising and important finding in the
context of antiscarring therapy, because cell migration around
wounds  significantly  contributes  to  the  formation  of  scar
tissue. Its ability to inhibit cell motility may render TFPI-2 a
promising candidate for novel therapies for preventing or
reducing  unwanted  wound-healing  scars  after  glaucoma
drainage surgery.
In  summary,  we  evaluated  the  effect  of  endogenous
TFPI-2 of hTCFs on cells’ proliferation and migration in vitro,
showing  that  TFPI-2  significantly  inhibits  cell  migration
without inducing apoptosis. This makes it a promising drug
for regulating wound healing following glaucoma surgery.
Figure  5.  Overexpressioin  of  TFPI-2
reduces hTCF migration in the scratch-
wound  assay.  A-I:  Phase  contrast
images  of  migration  of  F-P  and  F-
TFPI-2  treated  with  or  without  anti-
TFPI-2 antibodies wounded with 1 mm
strips at day T0, T1, and T2. Bars, 200
μm. J: Quantification of cell migration
at day T1 and T2. Mean values from 3
different experiments are shown for F-
P, F-TFPI-2 with or without anti-TFPI-2
Ab  in  culture  medium.  The  double
asterisk denotes a significant difference
from  F-P  and  F-TFPI-2  treated  with
anti-TFPI-2 antibodies versus F-TFPI-2
at p<0.001.
Molecular Vision 2009; 15:2306-2312 <http://www.molvis.org/molvis/v15/a247> © 2009 Molecular Vision
2311Further studies are needed to investigate the gene transduction
strategies of TFPI-2 and its activity in vivo.
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